A retrospective study to determine association between post-remission outcomes with measurable residual disease status and further modified by chosen induction (IC vs HMA/ven) in Acute Myeloid Leukemia patients
Latest Information Update: 09 Jan 2023
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Cytarabine; Venetoclax
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
Most Recent Events
- 09 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition